Clinical trial / 2005
Beta-glucan modulates nasal cytokine and eosinophil levels in allergic rhinitis patients.
In a double-blind trial, 24 patients with allergic rhinitis received beta-1,3-1,6-glucan or placebo for 12 weeks. Compared with placebo, glucan treatment significantly decreased nasal lavage levels of IL-4 (p = 0.027) and IL-5 (p = 0.04), while increasing IL-12 (p = 0.008). Nasal lavage eosinophil percentage also decreased significantly in the glucan group (p = 0.01), though peripheral blood eosinophils did not change.
- Study type
- Randomized controlled trial
- Who was studied
- 24 patients with allergic rhinitis mono-sensitized to Olea europea
- What was measured
- Nasal lavage cytokines and eosinophil counts
THE PAPER
Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study.
Kirmaz C, Bayrak P, Yilmaz O, Yuksel H. Eur Cytokine Netw, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.